Abstract

With the development of the material science, the clinical application of stable nuclide microspheres has become a hot spot of endovascular treatment of liver cancer in last 10 years. Transarterial radioembolization came to be a new selection to treat hepatocellular carcinoma. The characteristics of the radioactive microsphere determine obvious different between TARE and TACE. For early HCC, TARE as the degradation treatment or transition treatment waiting for liver transplantation.For advanced HCC, TARE as the treatment of unresectable advanced hepatocellular cancer. TARE as the rescue treatment of recurrence after liver resection. TARE as a treatment of HCC with portal vein tumor thrombus. How to make more patients in Asia countries such as China benefit, the optimization of treatment, indications of therapy, radioactive microsphere local production, health economics studies, all needed to further research.

This work is licensed under a Creative Commons Attribution 4.0 License.